Kratom-induced acute respiratory distress syndrome (ARDS)
  • Justine Chinnappan
    Department of Internal Medicine, Michigan State University at Hurley Medical Center, Flint, MI, USA https://orcid.org/0000-0002-6643-2549
  • Diane Casini
    Department of Internal Medicine, Michigan State University at Hurley Medical Center, Flint, MI, USA
  • Yasaman Navari
    Department of Internal Medicine, Michigan State University at Hurley Medical Center, Flint, MI, USA
  • Nageshwari Palanisamy
    Department of Internal Medicine, Michigan State University at Hurley Medical Center, Flint, MI, USA
  • Niraj Parikh
    Department of Internal Medicine, Michigan State University at Hurley Medical Center, Flint, MI, USA; Division of Pulmonary Critical Care, Michigan State University at Hurley Medical Center, Flint, MI, USA
  • Elfateh Seedahmed
    Department of Internal Medicine, Michigan State University at Hurley Medical Center, Flint, MI, USA; Division of Pulmonary Critical Care, Michigan State University at Hurley Medical Center, Flint, MI, USA

Keywords

kratom, Mitragyna speciosa, Acute respiratory distress syndrome

Abstract

The alkaloid derivatives of Mitragyna speciosa, commonly known as kratom, pose a threat to society due to its potential for abuse, adverse reactions and tendency to be used as self-medication for opioid withdrawal, pain and mood disorders. A number of deaths have been reported along with complications such as respiratory depression, cardiopulmonary arrest, torsade de pointes and seizures. Its various effects and potential are yet to be fully studied. We describe the case of a healthy young male who presented with progressive respiratory failure requiring mechanical ventilation. Imaging revealed multifocal lung infiltrates while extensive infectious and cardiac work-up was negative. Based on the clinical course, a diagnosis of acute respiratory distress syndrome (ARDS) caused by kratom was made. The patient showed gradual clinical improvement and was weaned off supplemental oxygen. This case highlights yet another adverse reaction to kratom and the growing threat posed by its use.

VIEW THE ENTIRE ARTICLE

References

  • Demick DS, Lee TT, Summers AT, El-Mallakh RS. Kratom: a growing substance of abuse in the United States. Ann Clin Psychiatry 2020;32:275–280.
  • Ya KM, Methaneethorn JP, Tran QBP, Trakulsrichai SM, Wananukul WM, Lohitnavy MP. Development of a physiologically based pharmacokinetic model of mitragynine, psychoactive alkaloid in kratom (Mitragyna Speciosa Korth.), in rats and humans. J Psychoactive Drugs 2021;53:127–139.
  • Stanciu C, Ahmed S, Gnanasegaram S, Gibson S, Penders T, Grundmann O, et al. Kratom as an opioid alternative: harm, or harm reduction? A systematic review of literature. Am J Drug Alcohol Abuse 2022;48:509–528.
  • Grundmann O. Patterns of kratom use and health impact in the US-Results from an online survey. Drug Alcohol Depend 2017;176:63–70.
  • Wilson LL, Harris HM, Eans SO, Brice-Tutt AC, Cirino TJ, Stacy HM, et al. Lyophilized kratom tea as a therapeutic option for opioid dependence. Drug Alcohol Depend 2020;216:108310.
  • Covvey JR, Vogel SM, Peckham AM, Evoy KE. Prevalence and characteristics of self-reported kratom use in a representative US general population sample. J Addict Dis 2020;38:506–513.
  • White CM. Pharmacologic and clinical assessment of kratom. Am J Health Syst Pharm 2018;75:261–267.
  • Sethi R, Hoang N, Ravishankar DA, McCracken M, Manzardo AM. Kratom (Mitragyna speciosa): friend or foe? Prim Care Companion CNS Disord 2020;22:19nr02507.
  • LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases; 2012.
  • Afzal H, Esang M, Rahman S. A case of kratom-induced seizures. Cureus 2020;12:e6588.
  • Botejue M, Walia G, Shahin O, Sharma J, Zackria R. Kratom-induced liver injury: a case series and clinical implications. Cureus 2021;13:e14679.
  • Sangani V, Sunnoqrot N, Gargis K, Ranabhotu A, Mubasher A, Pokal M. Unusual presentation of kratom overdose with rhabdomyolysis, transient hearing loss, and heart failure. J Investig Med High Impact Case Rep 2021;9:23247096211005069.
  • White CM. Pharmacologic and clinical assessment of kratom: an update. Am J Health Syst Pharm 2019;76:1915–1025.
  • Pathak V, Hahn C, Cabellon M, Aris R. Adult respiratory distress syndrome secondary to the use of herbal drug kratom. Am J Resp Crit Care Med 2014;189:A6492.
  • Jaliawala HA, Abdo T, Carlile PV. Kratom; a potential cause of acute respiratory distress syndrome. Am J Resp Crit Care Med 2018;197:A6604.
  • Matsunaga T, Morikawa Y, Kamase K, Horinouchi M, Sasajima Y, Suenami K, et al. Enhancement of endothelial barrier permeability by mitragynine. Biol Pharm Bull 2017;40:1779–1783.
  • Jittasopa W, Srisont S. The causes of death and pathological findings of kratom users: a 5-year retrospective analysis. Am J Forensic Med Pathol 2021;42:335–340.
  • Neerman MF, Frost RE, Deking J. A drug fatality involving kratom. J Forensic Sci 2013;58(Suppl 1):S278–279.
  • McIntyre IM, Trochta A, Stolberg S, Campman SC. Mitragynine 'kratom' related fatality: a case report with postmortem concentrations. J Anal Toxicol 2015;39:152–155.
  • Views: 1046
    HTML downloads: 863
    PDF downloads: 518


    Published: 2023-04-06
    Issue: 2023: Vol 10 No 4 (view)


    How to cite:
    1.
    Chinnappan J, Casini D, Navari Y, Palanisamy N, Parikh N, Seedahmed E. Kratom-induced acute respiratory distress syndrome (ARDS). EJCRIM 2023;10 doi:10.12890/2023_003835.

    Most read articles by the same author(s)